sunitinib accord
accord healthcare s.l.u. - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib vivanta 50 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 50 mg - sunitinibi
sunitinib vivanta 37.5 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 37.5 mg - sunitinibi
sunitinib vivanta 25 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 25 mg - sunitinibi
sunitinib vivanta 12.5 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 12.5 mg - sunitinibi
sunitinib krka 50 mg kapseli, kova
krka, d.d., novo mesto - sunitinib malate - kapseli, kova - 50 mg - sunitinibi
sunitinib krka 25 mg kapseli, kova
krka, d.d., novo mesto - sunitinib malate - kapseli, kova - 25 mg - sunitinibi
sunitinib krka 12.5 mg kapseli, kova
krka, d.d., novo mesto - sunitinib malate - kapseli, kova - 12.5 mg - sunitinibi
sunitinib avansor 50 mg kapseli, kova
avansor pharma oy - sunitinib malate - kapseli, kova - 50 mg - sunitinibi
sunitinib avansor 25 mg kapseli, kova
avansor pharma oy - sunitinib malate - kapseli, kova - 25 mg - sunitinibi